NCT06981806View on ClinicalTrials.gov

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Balixafortide

Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly

DRUG

Balixafortide

Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly

DRUG

Cosibelimab

Dose: 800 mg Route: IV (60 min) Frequency: Weekly

DRUG

Balixafortide

Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly

Trial Locations (1)

90048

Cedars-Sinai Cancer at SOCC, Los Angeles

All Listed Sponsors
lead

Arsen Osipov

OTHER